NASDAQ:CLSD
Clearside BioMedical, Inc Stock News
$1.31
-0.0100 (-0.758%)
At Close: May 16, 2024
Clearside Biomedical, Inc. (CLSD) Reports Q4 Loss, Tops Revenue Estimates
07:49pm, Thursday, 09'th Mar 2023
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -23.08% and 111.54%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for t
ALPHARETTA, Ga., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical, Inc. (CLSD) Q3 2022 Earnings Call Transcript
04:41pm, Wednesday, 09'th Nov 2022
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q3 2022 Earnings Call Transcript November 9, 2022 8:30 AM ET Company Representatives George Lasezkay - Chief Executive Officer Tom Ciulla - Chief Medical Offi
Webcast and Conference Call on Wednesday, November 9, 2022 at 8:30 A.M. ET Hosted by Management and Including Key Opinion Leader, Arshad Khanani, M.D. Webcast and Conference Call on Wednesday, Novembe
Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022
07:05am, Wednesday, 02'nd Nov 2022
ALPHARETTA, Ga., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022 CLS-AX Wet AMD Clinical Trial Data from OASIS Cohorts 3 & 4 Expected in November 2022
Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022
07:05am, Thursday, 25'th Aug 2022
ALPHARETTA, Ga., Aug. 25, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
Clearside Biomedical Inc (CLSD) CEO George Lasezkay on Q2 2022 Results - Earnings Call Transcript
02:47pm, Tuesday, 09'th Aug 2022
Clearside Biomedical Inc (NASDAQ:CLSD ) Q2 2022 Earnings Conference Call August 9, 2022 8:30 AM ET Company Participants Jenny Kobin - Head of IR George Lasezkay - President, CEO and Director Tom Ciull
Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022
07:05am, Wednesday, 03'rd Aug 2022
ALPHARETTA, Ga., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022
07:05am, Wednesday, 27'th Jul 2022
ALPHARETTA, Ga., July 27, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the s
Clearside Biomedical, Inc.'s (CLSD) CEO George Lasezkay on Q1 2022 Results - Earnings Call Transcript
09:11pm, Wednesday, 11'th May 2022
Clearside Biomedical, Inc. (NASDAQ:CLSD ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Jenny Kobin - Investor Relations George Lasezkay - President and Chief Executive
Clearside Biomedical, Inc. (CLSD) Reports Q1 Loss, Misses Revenue Estimates
06:49pm, Wednesday, 11'th May 2022
Clearside Biomedical, Inc. (CLSD) delivered earnings and revenue surprises of -333.33% and 96.17%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the
Clearside Biomedical to Report First Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, May 11, 2022
07:05am, Friday, 29'th Apr 2022
ALPHARETTA, Ga., April 29, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
Clearside Biomedical: A Pivotal 2022 Ahead
06:19am, Wednesday, 13'th Apr 2022
XIPERE was officially launched by partner Bausch + Lomb in Q1 2022. CLS-AX cohort 3 has fully enrolled with a fourth cohort to be enrolled Q2 2022 pending safety review of cohort 3.
Clearside Biomedical to Present at the Needham Virtual Healthcare Conference
07:05am, Wednesday, 06'th Apr 2022
ALPHARETTA, Ga., April 06, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the
